ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) has bolstered its capabilities at its European operations, it told investors on Monday.
The biotech group is a therapeutic antibody discovery company, offering its services around the world, and revealed it is to integrate SGI-DNA Inc's benchtop automated DNA printer into its Utrecht laboratories in the Netherlands.
ImmunoPrecise Antibodies will thus become the first CRO (contract research organization) in Europe to integrate the BioXp 3200 system in its workflows as part of its vision for adopting breakthrough technologies in the discovery and manufacturing of antibodies.
READ: ImmunoPrecise Antibodies' Dutch subsidiary to take up new home at Europe's most competitive science region
"The BioXp 3200 system will greatly reduce our turnaround time for cloning activities in our discovery and manufacturing projects, positively impacting our manufacturing capacity," said Dr Jennifer Bath, the CEO and president of ImmunoPrecise, in a statement.
"Moreover, the BioXp 3200 enables additional avenues of synthetic biology, enhancing our ability to generate, analyze and screen large numbers of gene sequences for a variety of applications.
"It fits perfectly into our continuous implementation of new, emerging, and disruptive technologies," she added.
Dr Martin Hessing, general manager of Immunoprecise's Dutch subsidiary U-Protein Express, added: "By automating rapid DNA synthesis, we will put IPA in a competitive position, allowing faster delivery of our antibodies."
Last week, the group said U-Protein Express had struck a long term lease at the new multi-tenant facility at the Utrecht Science Park, which will encourage collaborations in the life sciences space.
"The investments we are making in our European operations are a strong reflection of ImunoPrecise's position in the marketplace and positive outlook for the future," Dr Bath had said.
"The Accelerator provides state-of-the-art facilities that enable our talented team to respond to the increasing demand for our services and innovative technologies."
Contact the author at giles@proactiveinvestors.com
